Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 14/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.54 |
| ▸ | KMO | O15229 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1400067 | 1.00 | SCN9A (0.56) | SCN9ACYP2C9CYP3A4CYP2D6PTGER1 | |
| SCHEMBL1400209 | 0.87 | SCN9A (0.65) | SCN9ACYP2C9CYP3A4CYP2D6PDK2 | |
| SCHEMBL4507814 | 0.87 | SCN9A (0.55) | SCN9ACYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1400086 | 0.83 | SCN9A (0.57) | SCN9ACYP2C9CYP3A4CYP2D6FFAR1 | |
| SCHEMBL4754489 | 0.83 | SCN9A (0.52) | SCN9ACYP2C9CYP3A4CYP2D6FFAR1 | |
| SCHEMBL536004 | 0.83 | FFAR4 (0.59) | PDK2 | |
| SCHEMBL536003 | 0.82 | RXRA (0.50) | PDK2 | |
| SCHEMBL21942059 | 0.82 | SYK (0.56) | PDK2 | |
| SCHEMBL14089991 | 0.82 | RXRA (0.54) | PTGER1PDK2 | |
| SCHEMBL1400239 | 0.81 | SCN9A (0.58) | SCN9ACYP2C9CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | SCN9A 2056/4885CYP2C9 2951/4885CYP3A4 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.